Skip to content
Advertisement

A sign marks an entrance to a Moderna building in Cambridge, Mass., on Monday, May 18, 2020. Moderna shares slipped Tuesday, April 11, 2023, after the COVID-19 vaccine developer said its potential flu vaccine needs more study in a late-stage clinical trial. (AP Photo/Bill Sikes) **FILE**

A sign marks an entrance to a Moderna building in Cambridge, Mass., on Monday, May 18, 2020. Moderna shares slipped Tuesday, April 11, 2023, after the COVID-19 vaccine developer said its potential flu vaccine needs more study in a late-stage clinical trial. (AP Photo/Bill Sikes) **FILE**

Featured Photo Galleries